Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study

Table 4 Percentage reduction of VAS and ODI at 1, 3, 6, and 12 months post injection and ADC value improvement at 1, 6, and 12 months post injection

Patient number	Reduction in VAS (%)				Reduction in ODI (%)				ADC value
Patient number	1 month	3 months	6 months	12 months	1 month	3 months	6 months	12 months	Pre treatment	1 month	6 months	12 months
1	50	75	63	50	30	40	25	25	1060	1290	1410	1456.7
2	15	15	57	100	41	47	65	91	1423.3	1413.3	1180	1160
3	17	17	17	33	33	27	20	13	1230	1480	1050	1193.3
4	29	0	100	86	36	38	82	82	1056.7	1230	1116.7	1086.7
5	0	25	25	50	19	31	31	75	1623.3	1470	1516.7	1583.3
6	29	29	57	14	17	31	58	36	1036.7	875	ND	ND
7	50	50	50	50	4	15	58	70	1173.3	992.3	1236.7	1063.3
8	33	67	50	50	25	31	59	63	834.3	800.7	998.7	965
9	50	33	50	50	38	25	19	56	1243.2	1366.7	1470	1496.7
10	14	43	29	43	50	48	60	57	1034.6	1226.7	1036.7	1053.3

VAS visual analogue scale, ODI Oswestry Disability Index, ADC apparent diffusion coefficient, ND not determined

ISSN: 1757-6512